nodes	percent_of_prediction	percent_of_DWPC	metapath
Pergolide—CYP3A4—Temozolomide—skin cancer	0.0745	0.233	CbGbCtD
Pergolide—CYP3A4—Imiquimod—skin cancer	0.0745	0.233	CbGbCtD
Pergolide—CYP2D6—Vemurafenib—skin cancer	0.0642	0.201	CbGbCtD
Pergolide—CYP3A4—Vismodegib—skin cancer	0.0516	0.162	CbGbCtD
Pergolide—CYP3A4—Vemurafenib—skin cancer	0.0408	0.128	CbGbCtD
Pergolide—DRD5—eyelid—skin cancer	0.0319	0.253	CbGeAlD
Pergolide—CYP3A4—Docetaxel—skin cancer	0.014	0.0438	CbGbCtD
Pergolide—DRD1—nerve—skin cancer	0.0065	0.0516	CbGeAlD
Pergolide—HTR2A—hindlimb—skin cancer	0.00416	0.0331	CbGeAlD
Pergolide—HTR1B—blood vessel—skin cancer	0.00413	0.0328	CbGeAlD
Pergolide—HTR1D—blood vessel—skin cancer	0.004	0.0318	CbGeAlD
Pergolide—DRD2—nerve—skin cancer	0.00384	0.0305	CbGeAlD
Pergolide—HTR2A—appendage—skin cancer	0.00357	0.0284	CbGeAlD
Pergolide—ADRA1D—epithelium—skin cancer	0.00261	0.0207	CbGeAlD
Pergolide—HTR2A—nerve—skin cancer	0.00253	0.0201	CbGeAlD
Pergolide—DRD5—lymphoid tissue—skin cancer	0.0025	0.0199	CbGeAlD
Pergolide—DRD5—female reproductive system—skin cancer	0.00241	0.0192	CbGeAlD
Pergolide—HTR2A—endothelium—skin cancer	0.00216	0.0171	CbGeAlD
Pergolide—DRD3—head—skin cancer	0.00215	0.0171	CbGeAlD
Pergolide—KCNH2—nipple—skin cancer	0.00215	0.0171	CbGeAlD
Pergolide—ADRA2C—nipple—skin cancer	0.00212	0.0168	CbGeAlD
Pergolide—HTR1D—connective tissue—skin cancer	0.00205	0.0163	CbGeAlD
Pergolide—DRD5—head—skin cancer	0.00202	0.016	CbGeAlD
Pergolide—HTR2A—blood vessel—skin cancer	0.00199	0.0158	CbGeAlD
Pergolide—ADRA1D—female reproductive system—skin cancer	0.00194	0.0154	CbGeAlD
Pergolide—HTR2B—skin of body—skin cancer	0.00172	0.0137	CbGeAlD
Pergolide—ADRA2A—nipple—skin cancer	0.00169	0.0134	CbGeAlD
Pergolide—ADRA1B—head—skin cancer	0.00165	0.0131	CbGeAlD
Pergolide—ADRA1D—head—skin cancer	0.00162	0.0128	CbGeAlD
Pergolide—DRD1—head—skin cancer	0.00154	0.0122	CbGeAlD
Pergolide—ADRA1A—epithelium—skin cancer	0.0015	0.0119	CbGeAlD
Pergolide—HTR1B—female reproductive system—skin cancer	0.0015	0.0119	CbGeAlD
Pergolide—HTR1D—female reproductive system—skin cancer	0.00145	0.0115	CbGeAlD
Pergolide—HTR2C—female reproductive system—skin cancer	0.00143	0.0114	CbGeAlD
Pergolide—HTR2A—neck—skin cancer	0.00142	0.0113	CbGeAlD
Pergolide—HTR2B—female reproductive system—skin cancer	0.00135	0.0107	CbGeAlD
Pergolide—HTR1B—head—skin cancer	0.00125	0.00992	CbGeAlD
Pergolide—ADRA2C—mammalian vulva—skin cancer	0.00124	0.00983	CbGeAlD
Pergolide—HTR1D—head—skin cancer	0.00121	0.0096	CbGeAlD
Pergolide—ADRA2A—connective tissue—skin cancer	0.0012	0.00952	CbGeAlD
Pergolide—HTR2C—head—skin cancer	0.0012	0.00951	CbGeAlD
Pergolide—ADRA1A—lymphoid tissue—skin cancer	0.00115	0.00916	CbGeAlD
Pergolide—HTR2B—head—skin cancer	0.00112	0.00893	CbGeAlD
Pergolide—KCNH2—female reproductive system—skin cancer	0.00107	0.00853	CbGeAlD
Pergolide—HTR2A—connective tissue—skin cancer	0.00102	0.0081	CbGeAlD
Pergolide—HTR1A—head—skin cancer	0.00101	0.008	CbGeAlD
Pergolide—ADRA2A—mammalian vulva—skin cancer	0.000987	0.00784	CbGeAlD
Pergolide—HTR2A—epithelium—skin cancer	0.000968	0.00769	CbGeAlD
Pergolide—ADRA1A—head—skin cancer	0.000929	0.00738	CbGeAlD
Pergolide—DRD2—head—skin cancer	0.000911	0.00723	CbGeAlD
Pergolide—KCNH2—head—skin cancer	0.000897	0.00712	CbGeAlD
Pergolide—ADRA2C—head—skin cancer	0.000885	0.00703	CbGeAlD
Pergolide—ADRA2A—female reproductive system—skin cancer	0.000846	0.00671	CbGeAlD
Pergolide—HTR2B—lymph node—skin cancer	0.000788	0.00625	CbGeAlD
Pergolide—Somnolence—Imiquimod—skin cancer	0.00072	0.00147	CcSEcCtD
Pergolide—HTR2A—female reproductive system—skin cancer	0.000719	0.00571	CbGeAlD
Pergolide—Alopecia—Bleomycin—skin cancer	0.000715	0.00146	CcSEcCtD
Pergolide—Sinusitis—Temozolomide—skin cancer	0.000714	0.00146	CcSEcCtD
Pergolide—Dyspepsia—Imiquimod—skin cancer	0.000713	0.00145	CcSEcCtD
Pergolide—ADRA2A—head—skin cancer	0.000706	0.00561	CbGeAlD
Pergolide—Pneumonia—Fluorouracil—skin cancer	0.000705	0.00144	CcSEcCtD
Pergolide—Decreased appetite—Imiquimod—skin cancer	0.000704	0.00144	CcSEcCtD
Pergolide—Atrial fibrillation—Docetaxel—skin cancer	0.000693	0.00141	CcSEcCtD
Pergolide—Pain—Imiquimod—skin cancer	0.000692	0.00141	CcSEcCtD
Pergolide—Acute coronary syndrome—Fluorouracil—skin cancer	0.000691	0.00141	CcSEcCtD
Pergolide—Myocardial infarction—Fluorouracil—skin cancer	0.000687	0.0014	CcSEcCtD
Pergolide—Neuropathy peripheral—Fluorouracil—skin cancer	0.000687	0.0014	CcSEcCtD
Pergolide—Dermatitis bullous—Docetaxel—skin cancer	0.000687	0.0014	CcSEcCtD
Pergolide—Hepatitis—Temozolomide—skin cancer	0.000683	0.00139	CcSEcCtD
Pergolide—Conjunctivitis—Fluorouracil—skin cancer	0.000681	0.00139	CcSEcCtD
Pergolide—Urinary tract infection—Fluorouracil—skin cancer	0.000681	0.00139	CcSEcCtD
Pergolide—Asthenia—Vemurafenib—skin cancer	0.000681	0.00139	CcSEcCtD
Pergolide—Hallucination—Temozolomide—skin cancer	0.000679	0.00139	CcSEcCtD
Pergolide—Pharyngitis—Temozolomide—skin cancer	0.000678	0.00138	CcSEcCtD
Pergolide—Chills—Dactinomycin—skin cancer	0.000677	0.00138	CcSEcCtD
Pergolide—Oedema peripheral—Temozolomide—skin cancer	0.000673	0.00137	CcSEcCtD
Pergolide—Pruritus—Vemurafenib—skin cancer	0.000672	0.00137	CcSEcCtD
Pergolide—Alopecia—Dactinomycin—skin cancer	0.000667	0.00136	CcSEcCtD
Pergolide—Feeling abnormal—Imiquimod—skin cancer	0.000667	0.00136	CcSEcCtD
Pergolide—CYP3A4—female reproductive system—skin cancer	0.000666	0.00529	CbGeAlD
Pergolide—Gastrointestinal pain—Imiquimod—skin cancer	0.000662	0.00135	CcSEcCtD
Pergolide—Epistaxis—Fluorouracil—skin cancer	0.000661	0.00135	CcSEcCtD
Pergolide—Visual impairment—Temozolomide—skin cancer	0.000658	0.00134	CcSEcCtD
Pergolide—Sinusitis—Fluorouracil—skin cancer	0.000658	0.00134	CcSEcCtD
Pergolide—CYP2D6—female reproductive system—skin cancer	0.000655	0.0052	CbGeAlD
Pergolide—Ill-defined disorder—Bleomycin—skin cancer	0.000654	0.00133	CcSEcCtD
Pergolide—Anaemia—Bleomycin—skin cancer	0.000651	0.00133	CcSEcCtD
Pergolide—Diarrhoea—Vemurafenib—skin cancer	0.00065	0.00132	CcSEcCtD
Pergolide—Migraine—Docetaxel—skin cancer	0.000646	0.00132	CcSEcCtD
Pergolide—Abdominal pain—Imiquimod—skin cancer	0.00064	0.00131	CcSEcCtD
Pergolide—Body temperature increased—Imiquimod—skin cancer	0.00064	0.00131	CcSEcCtD
Pergolide—Eye disorder—Temozolomide—skin cancer	0.000638	0.0013	CcSEcCtD
Pergolide—Tinnitus—Temozolomide—skin cancer	0.000637	0.0013	CcSEcCtD
Pergolide—Malaise—Bleomycin—skin cancer	0.000636	0.0013	CcSEcCtD
Pergolide—Leukopenia—Bleomycin—skin cancer	0.000631	0.00129	CcSEcCtD
Pergolide—Rhinitis—Fluorouracil—skin cancer	0.000631	0.00129	CcSEcCtD
Pergolide—KCNH2—lymph node—skin cancer	0.000628	0.00499	CbGeAlD
Pergolide—Dizziness—Vemurafenib—skin cancer	0.000628	0.00128	CcSEcCtD
Pergolide—Pharyngitis—Fluorouracil—skin cancer	0.000624	0.00127	CcSEcCtD
Pergolide—ADRA2C—lymph node—skin cancer	0.00062	0.00492	CbGeAlD
Pergolide—Ataxia—Docetaxel—skin cancer	0.000617	0.00126	CcSEcCtD
Pergolide—Cough—Bleomycin—skin cancer	0.000615	0.00125	CcSEcCtD
Pergolide—Chills—Temozolomide—skin cancer	0.000613	0.00125	CcSEcCtD
Pergolide—Dehydration—Docetaxel—skin cancer	0.000611	0.00124	CcSEcCtD
Pergolide—Ill-defined disorder—Dactinomycin—skin cancer	0.00061	0.00124	CcSEcCtD
Pergolide—Anaemia—Dactinomycin—skin cancer	0.000607	0.00124	CcSEcCtD
Pergolide—Liver function test abnormal—Docetaxel—skin cancer	0.000606	0.00124	CcSEcCtD
Pergolide—Vomiting—Vemurafenib—skin cancer	0.000604	0.00123	CcSEcCtD
Pergolide—Alopecia—Temozolomide—skin cancer	0.000603	0.00123	CcSEcCtD
Pergolide—Dry skin—Docetaxel—skin cancer	0.000602	0.00123	CcSEcCtD
Pergolide—HTR2A—head—skin cancer	0.000601	0.00477	CbGeAlD
Pergolide—Chest pain—Bleomycin—skin cancer	0.0006	0.00122	CcSEcCtD
Pergolide—Myalgia—Bleomycin—skin cancer	0.0006	0.00122	CcSEcCtD
Pergolide—Orthostatic hypotension—Docetaxel—skin cancer	0.0006	0.00122	CcSEcCtD
Pergolide—Rash—Vemurafenib—skin cancer	0.000599	0.00122	CcSEcCtD
Pergolide—Dermatitis—Vemurafenib—skin cancer	0.000598	0.00122	CcSEcCtD
Pergolide—Headache—Vemurafenib—skin cancer	0.000595	0.00121	CcSEcCtD
Pergolide—Discomfort—Bleomycin—skin cancer	0.000593	0.00121	CcSEcCtD
Pergolide—Malaise—Dactinomycin—skin cancer	0.000593	0.00121	CcSEcCtD
Pergolide—Leukopenia—Dactinomycin—skin cancer	0.000588	0.0012	CcSEcCtD
Pergolide—Dysgeusia—Temozolomide—skin cancer	0.000582	0.00119	CcSEcCtD
Pergolide—Asthenia—Imiquimod—skin cancer	0.000581	0.00118	CcSEcCtD
Pergolide—Confusional state—Bleomycin—skin cancer	0.00058	0.00118	CcSEcCtD
Pergolide—Oedema—Bleomycin—skin cancer	0.000575	0.00117	CcSEcCtD
Pergolide—Back pain—Temozolomide—skin cancer	0.000575	0.00117	CcSEcCtD
Pergolide—Pruritus—Imiquimod—skin cancer	0.000573	0.00117	CcSEcCtD
Pergolide—Infection—Bleomycin—skin cancer	0.000571	0.00117	CcSEcCtD
Pergolide—Dysphagia—Docetaxel—skin cancer	0.000567	0.00116	CcSEcCtD
Pergolide—Nausea—Vemurafenib—skin cancer	0.000564	0.00115	CcSEcCtD
Pergolide—Thrombocytopenia—Bleomycin—skin cancer	0.000563	0.00115	CcSEcCtD
Pergolide—Arrhythmia—Fluorouracil—skin cancer	0.000562	0.00115	CcSEcCtD
Pergolide—Myalgia—Dactinomycin—skin cancer	0.00056	0.00114	CcSEcCtD
Pergolide—Tremor—Temozolomide—skin cancer	0.000557	0.00114	CcSEcCtD
Pergolide—Alopecia—Fluorouracil—skin cancer	0.000556	0.00113	CcSEcCtD
Pergolide—Diarrhoea—Imiquimod—skin cancer	0.000554	0.00113	CcSEcCtD
Pergolide—Discomfort—Dactinomycin—skin cancer	0.000553	0.00113	CcSEcCtD
Pergolide—Angina pectoris—Docetaxel—skin cancer	0.000553	0.00113	CcSEcCtD
Pergolide—Ill-defined disorder—Temozolomide—skin cancer	0.000552	0.00112	CcSEcCtD
Pergolide—Anaemia—Temozolomide—skin cancer	0.000549	0.00112	CcSEcCtD
Pergolide—Anorexia—Bleomycin—skin cancer	0.000548	0.00112	CcSEcCtD
Pergolide—CYP2D6—head—skin cancer	0.000547	0.00434	CbGeAlD
Pergolide—Agitation—Temozolomide—skin cancer	0.000546	0.00111	CcSEcCtD
Pergolide—Hypotension—Bleomycin—skin cancer	0.000537	0.0011	CcSEcCtD
Pergolide—Oedema—Dactinomycin—skin cancer	0.000536	0.00109	CcSEcCtD
Pergolide—Malaise—Temozolomide—skin cancer	0.000536	0.00109	CcSEcCtD
Pergolide—Dizziness—Imiquimod—skin cancer	0.000535	0.00109	CcSEcCtD
Pergolide—Vertigo—Temozolomide—skin cancer	0.000534	0.00109	CcSEcCtD
Pergolide—Infection—Dactinomycin—skin cancer	0.000533	0.00109	CcSEcCtD
Pergolide—Leukopenia—Temozolomide—skin cancer	0.000532	0.00109	CcSEcCtD
Pergolide—Palpitations—Temozolomide—skin cancer	0.000525	0.00107	CcSEcCtD
Pergolide—Thrombocytopenia—Dactinomycin—skin cancer	0.000525	0.00107	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000524	0.00107	CcSEcCtD
Pergolide—Cough—Temozolomide—skin cancer	0.000519	0.00106	CcSEcCtD
Pergolide—Paraesthesia—Bleomycin—skin cancer	0.000516	0.00105	CcSEcCtD
Pergolide—Weight increased—Docetaxel—skin cancer	0.000516	0.00105	CcSEcCtD
Pergolide—Convulsion—Temozolomide—skin cancer	0.000515	0.00105	CcSEcCtD
Pergolide—Vomiting—Imiquimod—skin cancer	0.000515	0.00105	CcSEcCtD
Pergolide—Weight decreased—Docetaxel—skin cancer	0.000513	0.00105	CcSEcCtD
Pergolide—Hypertension—Temozolomide—skin cancer	0.000513	0.00105	CcSEcCtD
Pergolide—Dyspnoea—Bleomycin—skin cancer	0.000513	0.00105	CcSEcCtD
Pergolide—Anorexia—Dactinomycin—skin cancer	0.000511	0.00104	CcSEcCtD
Pergolide—Rash—Imiquimod—skin cancer	0.00051	0.00104	CcSEcCtD
Pergolide—Dermatitis—Imiquimod—skin cancer	0.00051	0.00104	CcSEcCtD
Pergolide—Pneumonia—Docetaxel—skin cancer	0.000509	0.00104	CcSEcCtD
Pergolide—Headache—Imiquimod—skin cancer	0.000507	0.00103	CcSEcCtD
Pergolide—Anaemia—Fluorouracil—skin cancer	0.000506	0.00103	CcSEcCtD
Pergolide—Myalgia—Temozolomide—skin cancer	0.000506	0.00103	CcSEcCtD
Pergolide—Arthralgia—Temozolomide—skin cancer	0.000506	0.00103	CcSEcCtD
Pergolide—Anxiety—Temozolomide—skin cancer	0.000504	0.00103	CcSEcCtD
Pergolide—Discomfort—Temozolomide—skin cancer	0.0005	0.00102	CcSEcCtD
Pergolide—Decreased appetite—Bleomycin—skin cancer	0.0005	0.00102	CcSEcCtD
Pergolide—Acute coronary syndrome—Docetaxel—skin cancer	0.000499	0.00102	CcSEcCtD
Pergolide—Renal failure—Docetaxel—skin cancer	0.000497	0.00101	CcSEcCtD
Pergolide—Myocardial infarction—Docetaxel—skin cancer	0.000496	0.00101	CcSEcCtD
Pergolide—Neuropathy peripheral—Docetaxel—skin cancer	0.000496	0.00101	CcSEcCtD
Pergolide—Dry mouth—Temozolomide—skin cancer	0.000495	0.00101	CcSEcCtD
Pergolide—ADRA2A—lymph node—skin cancer	0.000495	0.00393	CbGeAlD
Pergolide—Jaundice—Docetaxel—skin cancer	0.000493	0.00101	CcSEcCtD
Pergolide—Pain—Bleomycin—skin cancer	0.000492	0.001	CcSEcCtD
Pergolide—Conjunctivitis—Docetaxel—skin cancer	0.000492	0.001	CcSEcCtD
Pergolide—Leukopenia—Fluorouracil—skin cancer	0.00049	0.001	CcSEcCtD
Pergolide—Confusional state—Temozolomide—skin cancer	0.000489	0.000998	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000489	0.000997	CcSEcCtD
Pergolide—Oedema—Temozolomide—skin cancer	0.000485	0.000989	CcSEcCtD
Pergolide—Infection—Temozolomide—skin cancer	0.000482	0.000983	CcSEcCtD
Pergolide—Nausea—Imiquimod—skin cancer	0.000481	0.000981	CcSEcCtD
Pergolide—Epistaxis—Docetaxel—skin cancer	0.000477	0.000973	CcSEcCtD
Pergolide—Thrombocytopenia—Temozolomide—skin cancer	0.000475	0.000969	CcSEcCtD
Pergolide—Convulsion—Fluorouracil—skin cancer	0.000475	0.000968	CcSEcCtD
Pergolide—Feeling abnormal—Bleomycin—skin cancer	0.000474	0.000966	CcSEcCtD
Pergolide—Hyperhidrosis—Temozolomide—skin cancer	0.000469	0.000956	CcSEcCtD
Pergolide—Myalgia—Fluorouracil—skin cancer	0.000466	0.000951	CcSEcCtD
Pergolide—Chest pain—Fluorouracil—skin cancer	0.000466	0.000951	CcSEcCtD
Pergolide—Decreased appetite—Dactinomycin—skin cancer	0.000466	0.000951	CcSEcCtD
Pergolide—Anorexia—Temozolomide—skin cancer	0.000462	0.000943	CcSEcCtD
Pergolide—Discomfort—Fluorouracil—skin cancer	0.000461	0.000939	CcSEcCtD
Pergolide—Pain—Dactinomycin—skin cancer	0.000459	0.000935	CcSEcCtD
Pergolide—Rhinitis—Docetaxel—skin cancer	0.000455	0.000928	CcSEcCtD
Pergolide—Body temperature increased—Bleomycin—skin cancer	0.000455	0.000927	CcSEcCtD
Pergolide—Hepatitis—Docetaxel—skin cancer	0.000454	0.000926	CcSEcCtD
Pergolide—Confusional state—Fluorouracil—skin cancer	0.000451	0.000919	CcSEcCtD
Pergolide—Pharyngitis—Docetaxel—skin cancer	0.000451	0.000919	CcSEcCtD
Pergolide—Oedema peripheral—Docetaxel—skin cancer	0.000447	0.000912	CcSEcCtD
Pergolide—Oedema—Fluorouracil—skin cancer	0.000447	0.000912	CcSEcCtD
Pergolide—Infection—Fluorouracil—skin cancer	0.000444	0.000906	CcSEcCtD
Pergolide—Feeling abnormal—Dactinomycin—skin cancer	0.000442	0.000901	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000442	0.000901	CcSEcCtD
Pergolide—Insomnia—Temozolomide—skin cancer	0.000439	0.000895	CcSEcCtD
Pergolide—Gastrointestinal pain—Dactinomycin—skin cancer	0.000439	0.000894	CcSEcCtD
Pergolide—Thrombocytopenia—Fluorouracil—skin cancer	0.000438	0.000892	CcSEcCtD
Pergolide—Visual impairment—Docetaxel—skin cancer	0.000438	0.000892	CcSEcCtD
Pergolide—Tachycardia—Fluorouracil—skin cancer	0.000436	0.00089	CcSEcCtD
Pergolide—Paraesthesia—Temozolomide—skin cancer	0.000436	0.000888	CcSEcCtD
Pergolide—Dyspnoea—Temozolomide—skin cancer	0.000433	0.000882	CcSEcCtD
Pergolide—Somnolence—Temozolomide—skin cancer	0.000431	0.000879	CcSEcCtD
Pergolide—Dyspepsia—Temozolomide—skin cancer	0.000427	0.000871	CcSEcCtD
Pergolide—Anorexia—Fluorouracil—skin cancer	0.000426	0.000869	CcSEcCtD
Pergolide—Eye disorder—Docetaxel—skin cancer	0.000424	0.000865	CcSEcCtD
Pergolide—Abdominal pain—Dactinomycin—skin cancer	0.000424	0.000865	CcSEcCtD
Pergolide—Body temperature increased—Dactinomycin—skin cancer	0.000424	0.000865	CcSEcCtD
Pergolide—Decreased appetite—Temozolomide—skin cancer	0.000422	0.00086	CcSEcCtD
Pergolide—Hypotension—Fluorouracil—skin cancer	0.000418	0.000852	CcSEcCtD
Pergolide—Pain—Temozolomide—skin cancer	0.000415	0.000846	CcSEcCtD
Pergolide—Constipation—Temozolomide—skin cancer	0.000415	0.000846	CcSEcCtD
Pergolide—Asthenia—Bleomycin—skin cancer	0.000413	0.000841	CcSEcCtD
Pergolide—Chills—Docetaxel—skin cancer	0.000407	0.000831	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000407	0.00083	CcSEcCtD
Pergolide—Pruritus—Bleomycin—skin cancer	0.000407	0.00083	CcSEcCtD
Pergolide—Arrhythmia—Docetaxel—skin cancer	0.000406	0.000827	CcSEcCtD
Pergolide—Insomnia—Fluorouracil—skin cancer	0.000404	0.000824	CcSEcCtD
Pergolide—Paraesthesia—Fluorouracil—skin cancer	0.000401	0.000818	CcSEcCtD
Pergolide—Alopecia—Docetaxel—skin cancer	0.000401	0.000818	CcSEcCtD
Pergolide—Feeling abnormal—Temozolomide—skin cancer	0.0004	0.000815	CcSEcCtD
Pergolide—Dyspnoea—Fluorouracil—skin cancer	0.000399	0.000813	CcSEcCtD
Pergolide—Somnolence—Fluorouracil—skin cancer	0.000397	0.00081	CcSEcCtD
Pergolide—Gastrointestinal pain—Temozolomide—skin cancer	0.000397	0.000809	CcSEcCtD
Pergolide—Dyspepsia—Fluorouracil—skin cancer	0.000394	0.000802	CcSEcCtD
Pergolide—Decreased appetite—Fluorouracil—skin cancer	0.000389	0.000792	CcSEcCtD
Pergolide—Dysgeusia—Docetaxel—skin cancer	0.000387	0.000789	CcSEcCtD
Pergolide—Asthenia—Dactinomycin—skin cancer	0.000385	0.000785	CcSEcCtD
Pergolide—Abdominal pain—Temozolomide—skin cancer	0.000384	0.000782	CcSEcCtD
Pergolide—Body temperature increased—Temozolomide—skin cancer	0.000384	0.000782	CcSEcCtD
Pergolide—Back pain—Docetaxel—skin cancer	0.000382	0.00078	CcSEcCtD
Pergolide—Pain—Fluorouracil—skin cancer	0.000382	0.000779	CcSEcCtD
Pergolide—Feeling abnormal—Fluorouracil—skin cancer	0.000368	0.000751	CcSEcCtD
Pergolide—Diarrhoea—Dactinomycin—skin cancer	0.000367	0.000748	CcSEcCtD
Pergolide—Vomiting—Bleomycin—skin cancer	0.000366	0.000746	CcSEcCtD
Pergolide—Anaemia—Docetaxel—skin cancer	0.000365	0.000745	CcSEcCtD
Pergolide—Rash—Bleomycin—skin cancer	0.000363	0.000739	CcSEcCtD
Pergolide—Dermatitis—Bleomycin—skin cancer	0.000362	0.000739	CcSEcCtD
Pergolide—Syncope—Docetaxel—skin cancer	0.000355	0.000723	CcSEcCtD
Pergolide—Leukopenia—Docetaxel—skin cancer	0.000354	0.000722	CcSEcCtD
Pergolide—Body temperature increased—Fluorouracil—skin cancer	0.000353	0.000721	CcSEcCtD
Pergolide—Palpitations—Docetaxel—skin cancer	0.000349	0.000712	CcSEcCtD
Pergolide—Asthenia—Temozolomide—skin cancer	0.000348	0.00071	CcSEcCtD
Pergolide—Loss of consciousness—Docetaxel—skin cancer	0.000347	0.000709	CcSEcCtD
Pergolide—Cough—Docetaxel—skin cancer	0.000345	0.000703	CcSEcCtD
Pergolide—Pruritus—Temozolomide—skin cancer	0.000343	0.0007	CcSEcCtD
Pergolide—Convulsion—Docetaxel—skin cancer	0.000343	0.000698	CcSEcCtD
Pergolide—Nausea—Bleomycin—skin cancer	0.000342	0.000697	CcSEcCtD
Pergolide—Hypertension—Docetaxel—skin cancer	0.000341	0.000696	CcSEcCtD
Pergolide—Vomiting—Dactinomycin—skin cancer	0.000341	0.000695	CcSEcCtD
Pergolide—Rash—Dactinomycin—skin cancer	0.000338	0.00069	CcSEcCtD
Pergolide—Chest pain—Docetaxel—skin cancer	0.000337	0.000686	CcSEcCtD
Pergolide—Arthralgia—Docetaxel—skin cancer	0.000337	0.000686	CcSEcCtD
Pergolide—Myalgia—Docetaxel—skin cancer	0.000337	0.000686	CcSEcCtD
Pergolide—Diarrhoea—Temozolomide—skin cancer	0.000332	0.000677	CcSEcCtD
Pergolide—Dry mouth—Docetaxel—skin cancer	0.000329	0.000671	CcSEcCtD
Pergolide—Confusional state—Docetaxel—skin cancer	0.000325	0.000663	CcSEcCtD
Pergolide—Oedema—Docetaxel—skin cancer	0.000323	0.000658	CcSEcCtD
Pergolide—Dizziness—Temozolomide—skin cancer	0.000321	0.000654	CcSEcCtD
Pergolide—Infection—Docetaxel—skin cancer	0.000321	0.000654	CcSEcCtD
Pergolide—Nausea—Dactinomycin—skin cancer	0.000319	0.00065	CcSEcCtD
Pergolide—Shock—Docetaxel—skin cancer	0.000317	0.000647	CcSEcCtD
Pergolide—Pruritus—Fluorouracil—skin cancer	0.000316	0.000645	CcSEcCtD
Pergolide—Thrombocytopenia—Docetaxel—skin cancer	0.000316	0.000644	CcSEcCtD
Pergolide—Tachycardia—Docetaxel—skin cancer	0.000315	0.000642	CcSEcCtD
Pergolide—Vomiting—Temozolomide—skin cancer	0.000308	0.000629	CcSEcCtD
Pergolide—Anorexia—Docetaxel—skin cancer	0.000308	0.000627	CcSEcCtD
Pergolide—Rash—Temozolomide—skin cancer	0.000306	0.000624	CcSEcCtD
Pergolide—Diarrhoea—Fluorouracil—skin cancer	0.000306	0.000624	CcSEcCtD
Pergolide—Dermatitis—Temozolomide—skin cancer	0.000306	0.000623	CcSEcCtD
Pergolide—Headache—Temozolomide—skin cancer	0.000304	0.00062	CcSEcCtD
Pergolide—Hypotension—Docetaxel—skin cancer	0.000301	0.000615	CcSEcCtD
Pergolide—Dizziness—Fluorouracil—skin cancer	0.000296	0.000603	CcSEcCtD
Pergolide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000294	0.000599	CcSEcCtD
Pergolide—Insomnia—Docetaxel—skin cancer	0.000292	0.000595	CcSEcCtD
Pergolide—Paraesthesia—Docetaxel—skin cancer	0.00029	0.000591	CcSEcCtD
Pergolide—Nausea—Temozolomide—skin cancer	0.000288	0.000588	CcSEcCtD
Pergolide—Dyspnoea—Docetaxel—skin cancer	0.000288	0.000587	CcSEcCtD
Pergolide—Somnolence—Docetaxel—skin cancer	0.000287	0.000585	CcSEcCtD
Pergolide—Vomiting—Fluorouracil—skin cancer	0.000284	0.00058	CcSEcCtD
Pergolide—Dyspepsia—Docetaxel—skin cancer	0.000284	0.000579	CcSEcCtD
Pergolide—Rash—Fluorouracil—skin cancer	0.000282	0.000575	CcSEcCtD
Pergolide—Dermatitis—Fluorouracil—skin cancer	0.000282	0.000574	CcSEcCtD
Pergolide—Decreased appetite—Docetaxel—skin cancer	0.00028	0.000572	CcSEcCtD
Pergolide—Headache—Fluorouracil—skin cancer	0.00028	0.000571	CcSEcCtD
Pergolide—Pain—Docetaxel—skin cancer	0.000276	0.000563	CcSEcCtD
Pergolide—Constipation—Docetaxel—skin cancer	0.000276	0.000563	CcSEcCtD
Pergolide—Feeling abnormal—Docetaxel—skin cancer	0.000266	0.000542	CcSEcCtD
Pergolide—Nausea—Fluorouracil—skin cancer	0.000266	0.000541	CcSEcCtD
Pergolide—Gastrointestinal pain—Docetaxel—skin cancer	0.000264	0.000538	CcSEcCtD
Pergolide—Abdominal pain—Docetaxel—skin cancer	0.000255	0.00052	CcSEcCtD
Pergolide—Body temperature increased—Docetaxel—skin cancer	0.000255	0.00052	CcSEcCtD
Pergolide—Asthenia—Docetaxel—skin cancer	0.000231	0.000472	CcSEcCtD
Pergolide—Pruritus—Docetaxel—skin cancer	0.000228	0.000465	CcSEcCtD
Pergolide—Diarrhoea—Docetaxel—skin cancer	0.000221	0.00045	CcSEcCtD
Pergolide—Dizziness—Docetaxel—skin cancer	0.000213	0.000435	CcSEcCtD
Pergolide—Vomiting—Docetaxel—skin cancer	0.000205	0.000418	CcSEcCtD
Pergolide—Rash—Docetaxel—skin cancer	0.000203	0.000415	CcSEcCtD
Pergolide—Dermatitis—Docetaxel—skin cancer	0.000203	0.000414	CcSEcCtD
Pergolide—Headache—Docetaxel—skin cancer	0.000202	0.000412	CcSEcCtD
Pergolide—Nausea—Docetaxel—skin cancer	0.000192	0.000391	CcSEcCtD
Pergolide—ADRA1D—Signaling Pathways—FOXO4—skin cancer	3.16e-05	0.000494	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—FOXO4—skin cancer	3.16e-05	0.000494	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—PTGER4—skin cancer	3.12e-05	0.000487	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—PTGER4—skin cancer	3.1e-05	0.000485	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PTCH1—skin cancer	3.1e-05	0.000484	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—SMO—skin cancer	3.1e-05	0.000484	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PTCH1—skin cancer	3.05e-05	0.000477	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—SMO—skin cancer	3.05e-05	0.000477	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—CSPG4—skin cancer	3.04e-05	0.000476	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—PTGER4—skin cancer	3.01e-05	0.000471	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—PTGER4—skin cancer	2.97e-05	0.000464	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—SHH—skin cancer	2.96e-05	0.000464	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—RASA1—skin cancer	2.95e-05	0.000461	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—SHH—skin cancer	2.92e-05	0.000456	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—RASA1—skin cancer	2.9e-05	0.000453	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—SHH—skin cancer	2.86e-05	0.000447	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—FOXO4—skin cancer	2.85e-05	0.000446	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—RASA1—skin cancer	2.84e-05	0.000444	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PTCH1—skin cancer	2.81e-05	0.000439	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—SMO—skin cancer	2.81e-05	0.000439	CbGpPWpGaD
Pergolide—ADRA2B—Hemostasis—NRAS—skin cancer	2.8e-05	0.000437	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—SMO—skin cancer	2.76e-05	0.000432	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PTCH1—skin cancer	2.76e-05	0.000432	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—FOXO4—skin cancer	2.75e-05	0.00043	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—FOXO4—skin cancer	2.74e-05	0.000428	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—PTGER4—skin cancer	2.74e-05	0.000428	CbGpPWpGaD
Pergolide—DRD5—Signaling by GPCR—NRAS—skin cancer	2.71e-05	0.000424	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PTCH1—skin cancer	2.71e-05	0.000423	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—SMO—skin cancer	2.71e-05	0.000423	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—PTGER4—skin cancer	2.69e-05	0.000421	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—FOXO4—skin cancer	2.66e-05	0.000416	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—SHH—skin cancer	2.65e-05	0.000415	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—RASA1—skin cancer	2.64e-05	0.000412	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—PTGER4—skin cancer	2.64e-05	0.000412	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—FOXO4—skin cancer	2.62e-05	0.00041	CbGpPWpGaD
Pergolide—ADRA2C—Hemostasis—NRAS—skin cancer	2.61e-05	0.000408	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—BRAF—skin cancer	2.55e-05	0.000398	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—SMO—skin cancer	2.52e-05	0.000393	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PTCH1—skin cancer	2.52e-05	0.000393	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PLIN2—skin cancer	2.47e-05	0.000386	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TERT—skin cancer	2.46e-05	0.000385	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—PTGER4—skin cancer	2.45e-05	0.000383	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—FOXO4—skin cancer	2.42e-05	0.000378	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TERT—skin cancer	2.41e-05	0.000377	CbGpPWpGaD
Pergolide—ADRA2B—Hemostasis—KRAS—skin cancer	2.41e-05	0.000376	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—FOXO4—skin cancer	2.38e-05	0.000372	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TERT—skin cancer	2.37e-05	0.000371	CbGpPWpGaD
Pergolide—DRD5—Signaling by GPCR—KRAS—skin cancer	2.33e-05	0.000365	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—FOXO4—skin cancer	2.33e-05	0.000364	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—ERCC2—skin cancer	2.27e-05	0.000355	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TERT—skin cancer	2.27e-05	0.000354	CbGpPWpGaD
Pergolide—ADRA2C—Hemostasis—KRAS—skin cancer	2.25e-05	0.000351	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—FOXO4—skin cancer	2.16e-05	0.000338	CbGpPWpGaD
Pergolide—ADRA2B—Hemostasis—TP53—skin cancer	2.14e-05	0.000334	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TERT—skin cancer	2.14e-05	0.000334	CbGpPWpGaD
Pergolide—ADRA2A—Hemostasis—NRAS—skin cancer	2.12e-05	0.000332	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TERT—skin cancer	2.11e-05	0.00033	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TERT—skin cancer	2.11e-05	0.00033	CbGpPWpGaD
Pergolide—HTR1D—Signaling by GPCR—NRAS—skin cancer	2.08e-05	0.000325	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—ENO2—skin cancer	2.07e-05	0.000323	CbGpPWpGaD
Pergolide—ADRA2B—Hemostasis—HRAS—skin cancer	2.04e-05	0.00032	CbGpPWpGaD
Pergolide—HTR1B—Signaling by GPCR—NRAS—skin cancer	2.03e-05	0.000318	CbGpPWpGaD
Pergolide—DRD4—Signaling by GPCR—NRAS—skin cancer	2e-05	0.000313	CbGpPWpGaD
Pergolide—ADRA2C—Hemostasis—TP53—skin cancer	2e-05	0.000312	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—CSPG4—skin cancer	1.99e-05	0.000311	CbGpPWpGaD
Pergolide—DRD5—Signaling by GPCR—HRAS—skin cancer	1.98e-05	0.00031	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—BRAF—skin cancer	1.95e-05	0.000305	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—BRAF—skin cancer	1.91e-05	0.000299	CbGpPWpGaD
Pergolide—ADRA2C—Hemostasis—HRAS—skin cancer	1.91e-05	0.000299	CbGpPWpGaD
Pergolide—HTR2B—Signaling by GPCR—NRAS—skin cancer	1.91e-05	0.000299	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TERT—skin cancer	1.9e-05	0.000298	CbGpPWpGaD
Pergolide—DRD5—Signaling by GPCR—IL6—skin cancer	1.9e-05	0.000297	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—BRAF—skin cancer	1.88e-05	0.000294	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—ERCC2—skin cancer	1.84e-05	0.000288	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TERT—skin cancer	1.84e-05	0.000287	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TERT—skin cancer	1.83e-05	0.000286	CbGpPWpGaD
Pergolide—ADRA2A—Hemostasis—KRAS—skin cancer	1.83e-05	0.000285	CbGpPWpGaD
Pergolide—DRD1—Signaling by GPCR—NRAS—skin cancer	1.8e-05	0.000282	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—BRAF—skin cancer	1.79e-05	0.000281	CbGpPWpGaD
Pergolide—HTR1D—Signaling by GPCR—KRAS—skin cancer	1.79e-05	0.000279	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TERT—skin cancer	1.78e-05	0.000278	CbGpPWpGaD
Pergolide—ADRA1D—Signaling by GPCR—NRAS—skin cancer	1.78e-05	0.000278	CbGpPWpGaD
Pergolide—DRD3—Signaling by GPCR—NRAS—skin cancer	1.78e-05	0.000278	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TERT—skin cancer	1.75e-05	0.000274	CbGpPWpGaD
Pergolide—HTR1B—Signaling by GPCR—KRAS—skin cancer	1.75e-05	0.000274	CbGpPWpGaD
Pergolide—DRD4—Signaling by GPCR—KRAS—skin cancer	1.72e-05	0.000269	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—BRAF—skin cancer	1.69e-05	0.000265	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—BRAF—skin cancer	1.67e-05	0.000261	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—BRAF—skin cancer	1.67e-05	0.000261	CbGpPWpGaD
Pergolide—HTR2B—Signaling by GPCR—KRAS—skin cancer	1.64e-05	0.000257	CbGpPWpGaD
Pergolide—ADRA2A—Hemostasis—TP53—skin cancer	1.62e-05	0.000254	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TERT—skin cancer	1.61e-05	0.000252	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—NRAS—skin cancer	1.6e-05	0.000251	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—NRAS—skin cancer	1.6e-05	0.00025	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TERT—skin cancer	1.59e-05	0.000248	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TERT—skin cancer	1.55e-05	0.000243	CbGpPWpGaD
Pergolide—ADRA2A—Hemostasis—HRAS—skin cancer	1.55e-05	0.000243	CbGpPWpGaD
Pergolide—DRD1—Signaling by GPCR—KRAS—skin cancer	1.55e-05	0.000242	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—NRAS—skin cancer	1.55e-05	0.000242	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.54e-05	0.000241	CbGpPWpGaD
Pergolide—ADRA1D—Signaling by GPCR—KRAS—skin cancer	1.53e-05	0.000239	CbGpPWpGaD
Pergolide—DRD3—Signaling by GPCR—KRAS—skin cancer	1.53e-05	0.000239	CbGpPWpGaD
Pergolide—HTR1D—Signaling by GPCR—HRAS—skin cancer	1.52e-05	0.000238	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—BRAF—skin cancer	1.51e-05	0.000236	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—NRAS—skin cancer	1.5e-05	0.000234	CbGpPWpGaD
Pergolide—HTR1B—Signaling by GPCR—HRAS—skin cancer	1.49e-05	0.000233	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—NRAS—skin cancer	1.47e-05	0.000231	CbGpPWpGaD
Pergolide—DRD4—Signaling by GPCR—HRAS—skin cancer	1.46e-05	0.000229	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—BRAF—skin cancer	1.46e-05	0.000228	CbGpPWpGaD
Pergolide—HTR1D—Signaling by GPCR—IL6—skin cancer	1.45e-05	0.000227	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—BRAF—skin cancer	1.45e-05	0.000226	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TERT—skin cancer	1.44e-05	0.000226	CbGpPWpGaD
Pergolide—HTR1B—Signaling by GPCR—IL6—skin cancer	1.42e-05	0.000223	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—BRAF—skin cancer	1.41e-05	0.00022	CbGpPWpGaD
Pergolide—DRD4—Signaling by GPCR—IL6—skin cancer	1.4e-05	0.000219	CbGpPWpGaD
Pergolide—HTR2B—Signaling by GPCR—HRAS—skin cancer	1.4e-05	0.000218	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—BRAF—skin cancer	1.39e-05	0.000217	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—KRAS—skin cancer	1.38e-05	0.000216	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—KRAS—skin cancer	1.38e-05	0.000216	CbGpPWpGaD
Pergolide—ADRA2C—Metabolism—PTGS2—skin cancer	1.36e-05	0.000213	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—NRAS—skin cancer	1.36e-05	0.000213	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ENO2—skin cancer	1.35e-05	0.000211	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—NRAS—skin cancer	1.34e-05	0.000209	CbGpPWpGaD
Pergolide—HTR2B—Signaling by GPCR—IL6—skin cancer	1.34e-05	0.000209	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—KRAS—skin cancer	1.33e-05	0.000208	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.33e-05	0.000207	CbGpPWpGaD
Pergolide—DRD1—Signaling by GPCR—HRAS—skin cancer	1.32e-05	0.000206	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—NRAS—skin cancer	1.31e-05	0.000205	CbGpPWpGaD
Pergolide—ADRA1D—Signaling by GPCR—HRAS—skin cancer	1.3e-05	0.000203	CbGpPWpGaD
Pergolide—DRD3—Signaling by GPCR—HRAS—skin cancer	1.3e-05	0.000203	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—KRAS—skin cancer	1.29e-05	0.000202	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—BRAF—skin cancer	1.28e-05	0.0002	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—KRAS—skin cancer	1.27e-05	0.000199	CbGpPWpGaD
Pergolide—DRD1—Signaling by GPCR—IL6—skin cancer	1.26e-05	0.000197	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—BRAF—skin cancer	1.26e-05	0.000197	CbGpPWpGaD
Pergolide—ADRA1D—Signaling by GPCR—IL6—skin cancer	1.24e-05	0.000195	CbGpPWpGaD
Pergolide—DRD3—Signaling by GPCR—IL6—skin cancer	1.24e-05	0.000195	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—BRAF—skin cancer	1.23e-05	0.000193	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—NRAS—skin cancer	1.23e-05	0.000192	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—TP53—skin cancer	1.22e-05	0.000192	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—NRAS—skin cancer	1.22e-05	0.00019	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—ERCC2—skin cancer	1.2e-05	0.000188	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—NRAS—skin cancer	1.2e-05	0.000188	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—NRAS—skin cancer	1.18e-05	0.000185	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—HRAS—skin cancer	1.17e-05	0.000184	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—HRAS—skin cancer	1.17e-05	0.000183	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—KRAS—skin cancer	1.17e-05	0.000183	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—KRAS—skin cancer	1.15e-05	0.00018	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—BRAF—skin cancer	1.14e-05	0.000179	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—HRAS—skin cancer	1.13e-05	0.000177	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—NRAS—skin cancer	1.13e-05	0.000176	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—KRAS—skin cancer	1.13e-05	0.000176	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—HRAS—skin cancer	1.13e-05	0.000176	CbGpPWpGaD
Pergolide—ADRA2B—Signaling by GPCR—IL6—skin cancer	1.12e-05	0.000176	CbGpPWpGaD
Pergolide—DRD5—Signaling Pathways—IL6—skin cancer	1.12e-05	0.000175	CbGpPWpGaD
Pergolide—ADRA2A—Metabolism—PTGS2—skin cancer	1.11e-05	0.000173	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—HRAS—skin cancer	1.1e-05	0.000171	CbGpPWpGaD
Pergolide—HTR1A—Signaling by GPCR—IL6—skin cancer	1.08e-05	0.00017	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—HRAS—skin cancer	1.08e-05	0.000169	CbGpPWpGaD
Pergolide—HTR2C—Signaling by GPCR—IL6—skin cancer	1.08e-05	0.000169	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—NRAS—skin cancer	1.06e-05	0.000166	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—KRAS—skin cancer	1.06e-05	0.000165	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—NRAS—skin cancer	1.05e-05	0.000164	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—NRAS—skin cancer	1.05e-05	0.000164	CbGpPWpGaD
Pergolide—ADRA2C—Signaling by GPCR—IL6—skin cancer	1.05e-05	0.000164	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—KRAS—skin cancer	1.05e-05	0.000164	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—KRAS—skin cancer	1.03e-05	0.000162	CbGpPWpGaD
Pergolide—ADRA1B—Signaling by GPCR—IL6—skin cancer	1.03e-05	0.000162	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—KRAS—skin cancer	1.02e-05	0.000159	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—HRAS—skin cancer	9.95e-06	0.000156	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—HRAS—skin cancer	9.79e-06	0.000153	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—KRAS—skin cancer	9.71e-06	0.000152	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—HRAS—skin cancer	9.58e-06	0.00015	CbGpPWpGaD
Pergolide—DRD2—Signaling by GPCR—IL6—skin cancer	9.52e-06	0.000149	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—NRAS—skin cancer	9.48e-06	0.000148	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—TP53—skin cancer	9.38e-06	0.000147	CbGpPWpGaD
Pergolide—HTR2A—Signaling by GPCR—IL6—skin cancer	9.37e-06	0.000147	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—TP53—skin cancer	9.19e-06	0.000144	CbGpPWpGaD
Pergolide—ADRA1A—Signaling by GPCR—IL6—skin cancer	9.17e-06	0.000143	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—KRAS—skin cancer	9.16e-06	0.000143	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—NRAS—skin cancer	9.15e-06	0.000143	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—NRAS—skin cancer	9.1e-06	0.000142	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—TP53—skin cancer	9.04e-06	0.000141	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—KRAS—skin cancer	9.03e-06	0.000141	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—KRAS—skin cancer	9.03e-06	0.000141	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—HRAS—skin cancer	8.97e-06	0.00014	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—HRAS—skin cancer	8.9e-06	0.000139	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—NRAS—skin cancer	8.85e-06	0.000138	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—HRAS—skin cancer	8.78e-06	0.000137	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—NRAS—skin cancer	8.71e-06	0.000136	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—HRAS—skin cancer	8.64e-06	0.000135	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—TP53—skin cancer	8.63e-06	0.000135	CbGpPWpGaD
Pergolide—HTR1D—Signaling Pathways—IL6—skin cancer	8.59e-06	0.000134	CbGpPWpGaD
Pergolide—ADRA2A—Signaling by GPCR—IL6—skin cancer	8.52e-06	0.000133	CbGpPWpGaD
Pergolide—HTR1B—Signaling Pathways—IL6—skin cancer	8.41e-06	0.000132	CbGpPWpGaD
Pergolide—DRD4—Signaling Pathways—IL6—skin cancer	8.27e-06	0.000129	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—HRAS—skin cancer	8.25e-06	0.000129	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—KRAS—skin cancer	8.16e-06	0.000128	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—TP53—skin cancer	8.14e-06	0.000127	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—NRAS—skin cancer	8.03e-06	0.000126	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—TP53—skin cancer	8.03e-06	0.000126	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—TP53—skin cancer	8.03e-06	0.000126	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—NRAS—skin cancer	7.9e-06	0.000124	CbGpPWpGaD
Pergolide—HTR2B—Signaling Pathways—IL6—skin cancer	7.9e-06	0.000124	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—KRAS—skin cancer	7.87e-06	0.000123	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—ERCC2—skin cancer	7.85e-06	0.000123	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—KRAS—skin cancer	7.83e-06	0.000123	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—HRAS—skin cancer	7.78e-06	0.000122	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—NRAS—skin cancer	7.74e-06	0.000121	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—HRAS—skin cancer	7.68e-06	0.00012	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—HRAS—skin cancer	7.68e-06	0.00012	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—KRAS—skin cancer	7.62e-06	0.000119	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—KRAS—skin cancer	7.5e-06	0.000117	CbGpPWpGaD
Pergolide—DRD1—Signaling Pathways—IL6—skin cancer	7.45e-06	0.000116	CbGpPWpGaD
Pergolide—ADRA1D—Signaling Pathways—IL6—skin cancer	7.35e-06	0.000115	CbGpPWpGaD
Pergolide—DRD3—Signaling Pathways—IL6—skin cancer	7.35e-06	0.000115	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—TP53—skin cancer	7.25e-06	0.000113	CbGpPWpGaD
Pergolide—CYP2D6—Metabolism—PTGS2—skin cancer	7.2e-06	0.000113	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—NRAS—skin cancer	7.19e-06	0.000112	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—TP53—skin cancer	7e-06	0.000109	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—TP53—skin cancer	6.96e-06	0.000109	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—HRAS—skin cancer	6.93e-06	0.000108	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—KRAS—skin cancer	6.91e-06	0.000108	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—KRAS—skin cancer	6.8e-06	0.000106	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—TP53—skin cancer	6.77e-06	0.000106	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—HRAS—skin cancer	6.69e-06	0.000105	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—TP53—skin cancer	6.66e-06	0.000104	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—KRAS—skin cancer	6.66e-06	0.000104	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—HRAS—skin cancer	6.66e-06	0.000104	CbGpPWpGaD
Pergolide—ADRA2B—Signaling Pathways—IL6—skin cancer	6.64e-06	0.000104	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—HRAS—skin cancer	6.48e-06	0.000101	CbGpPWpGaD
Pergolide—HTR1A—Signaling Pathways—IL6—skin cancer	6.41e-06	0.0001	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—HRAS—skin cancer	6.37e-06	9.97e-05	CbGpPWpGaD
Pergolide—HTR2C—Signaling Pathways—IL6—skin cancer	6.37e-06	9.97e-05	CbGpPWpGaD
Pergolide—ADRA2C—Signaling Pathways—IL6—skin cancer	6.2e-06	9.69e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—KRAS—skin cancer	6.19e-06	9.68e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—TP53—skin cancer	6.14e-06	9.61e-05	CbGpPWpGaD
Pergolide—ADRA1B—Signaling Pathways—IL6—skin cancer	6.1e-06	9.54e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—TP53—skin cancer	6.05e-06	9.46e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—TP53—skin cancer	5.92e-06	9.26e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—HRAS—skin cancer	5.88e-06	9.19e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—HRAS—skin cancer	5.78e-06	9.04e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—HRAS—skin cancer	5.66e-06	8.85e-05	CbGpPWpGaD
Pergolide—DRD2—Signaling Pathways—IL6—skin cancer	5.62e-06	8.8e-05	CbGpPWpGaD
Pergolide—HTR2A—Signaling Pathways—IL6—skin cancer	5.53e-06	8.65e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—TP53—skin cancer	5.5e-06	8.6e-05	CbGpPWpGaD
Pergolide—ADRA1A—Signaling Pathways—IL6—skin cancer	5.42e-06	8.47e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—HRAS—skin cancer	5.26e-06	8.23e-05	CbGpPWpGaD
Pergolide—ADRA2A—Signaling Pathways—IL6—skin cancer	5.03e-06	7.87e-05	CbGpPWpGaD
Pergolide—CYP3A4—Metabolism—PTGS2—skin cancer	4.71e-06	7.36e-05	CbGpPWpGaD
